Organon (OGN) Insider Alan Ezekowitz Buys $240K of Stock
Insider Alan Ezekowitz purchased 17,857 shares of Organon & Co. on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Alan Ezekowitz bought 17,857 shares of Organon & Co. ($OGN) at an average price of $13.44, worth about $239,998.08, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OGN is down 0.3% after 1 week, up 0.5% after 1 month and up 2.5% to date (from the $13.42 close on Jun 12, 2026).
OGN
Organon & Co.
Key Points
- Alan Ezekowitz bought 17,857 shares of Organon & Co. for about $240,000 on June 12, 2026, at a price of $13.44 per share.
- The stock is currently trading at $13.44, close to its 52-week high of $13.79, indicating strong recent performance.
- Other insiders, including Robert Essner and Helene Gayle, also bought 17,857 shares each on the same day.
Get $OGN trade alerts by text
We text you when insiders, Congress or big funds trade $OGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Organon & Co. alert may contain errors. Disclosures
Insider Buying and Selling at Organon & Co.
Alan Ezekowitz bought 17,857 shares of Organon & Co. (NYSE: OGN) for about $239,998.08 on June 12, 2026. This purchase came at a price of $13.44 per share. The transaction signals a personal investment in the company, which is known for its focus on women's health solutions.
Other Insiders Follow Suit
Ezekowitz wasn't alone in his buying spree. Other insiders, including Robert Essner, Helene Gayle, Rochelle Lazarus, Cynthia Patton, and Deborah Leone, each acquired 17,857 shares on the same day, also at $13.44 per share. Each of these transactions was valued at about $239,998.08, showing a collective confidence among the leadership in Organon’s future.
How Organon & Co. Stock Has Traded
Currently, Organon shares are trading at $13.44, which is close to its 52-week high of $13.79. The stock has seen a strong performance recently, moving up from its 52-week low of $5.69. Investors may take note of this upward trend as the company approaches its next earnings report.
Recent Earnings
Organon reported revenue of approximately $6.13 billion, but its revenue growth has seen a slight decline of 2.3%. The company's earnings per share (EPS) stands at $0.78, with a net margin of 3.41%. Investors will be looking forward to the next earnings report scheduled for November 9, 2026, to see how the company continues to perform in a challenging market.
What Organon & Co. Does
Organon & Co. focuses on developing health solutions for women, including a range of contraceptive and fertility products. The company serves various markets across the globe, which is crucial for its growth strategy. This insider buying may reflect a belief in the company's ongoing potential.
What’s Next for Organon
Investors will be watching for the upcoming earnings report on November 9, 2026, to evaluate the company's financial health and performance. With multiple insiders purchasing shares recently, it will be interesting to see if this trend continues as the company navigates its market challenges.
Related Filing Alerts
Source: Alan Ezekowitz's Form 4 filing on $OGN (Jun 12, 2026). Find the original filing: OGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts